Orzechowska-Juzwenko K, Pawlik J, Niewiński P, Milejski P, Dembowski J, Turek J, Goździk A, Swiebodzki L, Hora Z
Eur J Clin Pharmacol. 1994;46(5):481-3. doi: 10.1007/BF00191917.
The genetic oxidation polymorphism was determined in 160 healthy Polish volunteers from the south-west of Poland (Wrocław region), using sparteine as a model drug. The results of a Polish population study revealed a bimodal distribution of the sparteine metabolic ratio and showed the existence of two oxidation phenotypes designated as extensive and poor metabolizers. The frequency of poor metabolizers in our study (8.8%) compares well with most results of poor oxidation metabolizers in Caucasian populations.